Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma

Blood

Volumn 121, Issue 9, 2013, Pages 1604-1611

  Green, Michael R ^a,b   Gentles, Andrew J ^a,b   Nair, Ramesh V ^b   Irish, Jonathan M ^a,c   Kihira, Shingo ^a   Liu, Chih Long ^a   Kela, Itai ^a   Hopmans, Erik S ^a   Myklebust, June H ^a,d   Ji, Hanlee ^a   Plevritis, Sylvia K ^a,b   Levy, Ronald ^a,b   Alizadeh, Ash A ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Center for Cancer Systems Biology   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; EXOME; FOLLICULAR LYMPHOMA; GENE; GENE MUTATION; GENE TRANSLOCATION; GENOMICS; HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SOMATIC MUTATION;

EID: 84876460347     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-457283     Document Type: Article

References (33)

1. Bilalovic N, Blystad A, Golouh R, et al. Expression of bcl-6 and CD10 protein Is associated with longer overall survival and time to treatment failure in Follicular lymphoma. Am J Clin Pathol. 2004;121(1):34-42. (Pubitemid 38090151)
2. McLaughlin P, Grillo-Lopez A, Link B, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-2833. (Pubitemid 28363048)
3. Maloney D, Liles T, Czerwinski D, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2BS) in patients with recurrent B-cell lymphoma. Blood. 1994;84(8):2457-2466. (Pubitemid 24317376)
4. Irish J, Myklebust J, Alizadeh A, et al. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A. 2010;107(29):12747-12754.
5. Olejniczak S, Stewart C, Donohue K, Czuczman M. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest. 2006;35(1):93-114.
6. Horvat M, Kloboves P, Lavrencak J, Jezersek N. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma. Oncol Rep. 2010;24(4):1101-1107.
7. Hiraga J, Tomita A, Sugimoto T, et al. Downregulation of CD20 expression in B-cell lymphoma cells after treatment with rituximabcontaining combination chemotherapies: its prevalence and clinical significance. Blood. 2009; 113(20):4885-4893.
8. Williams M, Densmore J, Pawluczkowycz A, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol. 2006;177(10):7435-7443. (Pubitemid 44715114)
9. Johnson N, Boyle M, Bashashati A, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood. 2009;113(16):3773-3780.
10. Weiss L, Warnke R, Sklar J, Cleary M. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphoma. New Engl J Med. 1987;317(19):1185-1189. (Pubitemid 17150330)
11. Zelenetz A, Chu G, Galili N, et al. Enhanced detection of the t (14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis. Blood. 1991;78(6):1552-1560.
12. Ladetto M, Drandi D, Compagno M, et al. PCRdetectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. J Clin Oncol. 2003; 21(7):1398-1403. (Pubitemid 46606422)
13. Morin R, Mendez-Lago M, Mungall A, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360): 298-303.
14. Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471 (7337):189-195.
15. Dekker F, Haisma H. Histone acetyl transferases as emerging drug targets. Drug Discov Today. 2009;14(19-20):942-948.
16. Reya T, Morrison S, Clarke M, Weissman I. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111. (Pubitemid 33041634)
17. Weinberg O, Ai W, Mariappan M, Shum C, Levy R, Arber D. Minor BCL2 breakpoints in Follicular lymphoma; frequency and correlation with grade and disease presentation in 236 cases. J Mol Diagn. 2007;9(4):530-537. (Pubitemid 47434120)
18. Flaherty P, Natsoulis G, Muralidharan O, et al. Ultrasensitive detection of rare mutations using next-generation targeted resequencing. Nucleic Acids Res. 2012;40(1):e2.
19. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-1303.
20. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
21. Jan M, Snyder T, Corces-Zimmerman M, Weissman I, Quake S, Majeti R. Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4(149)149ra118.
22. Koboldt D, Zhang Q, Larson D, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568-576.
23. Chen J, Bardes E, Aronow B, Jegga A. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 2009; 37(Web Server Issue):W305-W311.
24. Brochet X, Lefranc M, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008;36(Web Server Issue):W503-W508.
25. Barak M, Zuckerman N, Edelman H, Unger R, Mehr R. IgTree: creating Immunoglobulin variable region gene lineage trees. J Immunol Methods. 2008;338(1-2):67-74.
26. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837.
27. Lohr J, Stojanov P, Lawrence M, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012; 109(10):3879-3884.
28. Weigert O, Kopp N, Lane A, et al. Molecular ontogeny of donor-derived Follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov. 2012;2(1):47-55.
29. Basso K, Saito O, Sumazin P, et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood. 2010;115(5):975-984.
30. Nik-Zainal S, Van-Loo P, Wedge D, et al. The life history of 21 breast cancers. Cell. 2012;149(5): 994-1007.
31. Shah S, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature. 2012;486(5): 395-399.
32. Walker B, Wardell C, Malchor L, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11; 14) myeloma. Blood. 2012;120(5):1077-1086.
33. Cerchietti L, Ghetu A, Zhu X, et al. A smallmolecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 2010;17(4):400-411.